Small Molecule Modulators of Beta-arrestins
Alem W. Kahsai,Natalia Pakharukova,Henry Y. Kwon,Kunal S. Shah,Jason G. Liang-Lin,Caroline T. del Real,Paul J. Shim,Mason A. Lee,Van A. Ngo,Bowie N. Shreiber,Samuel Liu,Allison M. Schwalb,Emmanuel F. Espinoza,Brittany N. Thomas,Cal A. Kunzle,Jeffrey S. Smith,Jialu Wang,Jihee Kim,Xingdong Zhang,Howard A. Rockman,Alex R. B. Thomsen,Lindsay A.M. Rein,Lei Shi,Seungkirl Ahn,Ali Masoudi,Robert J. Lefkowitz
DOI: https://doi.org/10.1101/2024.12.27.630464
2024-12-27
Abstract:Beta-arrestins are key regulators of G protein-coupled receptors (GPCRs), essential for modulating signaling pathways and physiological processes. While current pharmacological strategies target GPCR orthosteric and allosteric sites, as well as G protein transducers, comparable tools for studying beta-arrestins are lacking. Here, we present the discovery and characterization of novel small-molecule allosteric inhibitors of beta-arrestins through comprehensive biophysical, biochemical, pharmacological, and structural analyses. These inhibitors disrupt beta-arrestin interactions with agonist-activated GPCRs, impairing receptor internalization, desensitization, and beta-arrestin-mediated physiological functions. A cryo-EM structure of beta-arrestin1 in complex with the allosteric inhibitor Cmpd-5, complemented by molecular dynamics simulations and mutagenesis studies, reveals that Cmpd-5 binds within a cryptic cleft formed by the middle, C-, and lariat loops-a critical site for beta-arrestin activation and recruitment to GPCRs. Thus, Cmpd-5 acts as a molecular lock, hindering beta-arrestin1 activation via an allosteric mechanism. These findings introduce novel strategies and tools for probing beta-arrestin functions.
Biochemistry